Here’s what you’ll learn when you read this article: GLP‑1 and dual agonist drugs like tirzepatide have shown the ability to slow tumor growth in obesity‑linked cancers, especially in preclinical models. Early human…
Here’s what you’ll learn when you read this article: The FDA removed black box warnings for most systemic HRT products in late 2025, reshaping menopause care. Timing of therapy initiation now plays a…
How the 2025 Expert Consensus and MENO‑ABC Trial Challenge Old Rules Here’s what you’ll learn when you read this article: The 2025 expert consensus opens the door to case-by-case HRT use in low-risk…
Takeaways FGF21 and GDF15 analogs offer distinct mechanisms beyond GLP-1 for treating obesity and metabolic disease. Late-stage trials show promising effects on liver fat, appetite control, and thermogenesis with fewer GI side effects.…
Takeaways Brown fat activation raises calorie burn without suppressing appetite or affecting mood. Pharmacological BAT activation shows clinical promise with fewer side effects than older weight loss drugs. Combination strategies using BAT activators…
Takeaways Wearable nanobiosensors offer real-time hormone tracking through sweat or interstitial fluid. Closed-loop adaptive systems adjust HRT dosing based on live feedback instead of static lab tests. These technologies enhance precision and safety…
Takeaways Rapamycin may delay menopause by preserving ovarian reserve through targeted mTOR pathway inhibition. Reproductive aging impacts whole-body health, with genetics linking menopause timing to systemic longevity. Clinical trials like NCT05836025 mark a…
Takeaways MC4R agonists target the brain’s appetite center to support lasting weight maintenance after initial loss. Combining GLP‑1 and MC4R therapies enhances satiety control while minimizing metabolic rebound. Fountain of Youth SWFL leads…
Takeaways Bioengineered ovary scaffolds may one day restore hormone function more naturally than conventional HRT. These implants aim to mimic feedback loops and hormone cycles rather than deliver static doses. Clinical use remains…
Takeaways Bimagrumab plus GLP-1 therapy may preserve muscle while promoting near-total fat loss. Protecting lean mass improves long-term strength, metabolism, and quality of life. Functional outcomes, not just body composition, will shape future…